CLINICAL TRIALS PROFILE FOR CEFTAZIDIME
✉ Email this page to a colleague
All Clinical Trials for CEFTAZIDIME
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00173901 ↗ | Adverse Drug Reactions of Different Brands of Ceftazidime Injection | Unknown status | National Taiwan University Hospital | Phase 4 | 2001-03-01 | The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug. |
| NCT00210964 ↗ | Ceftobiprole in Hospital Acquired Pneumonia | Completed | Basilea Pharmaceutica | Phase 3 | 2005-04-01 | The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia. |
| NCT00229008 ↗ | Ceftobiprole in Hospital Acquired Pneumonia | Completed | Basilea Pharmaceutica | Phase 3 | 2005-11-01 | The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia. |
| NCT00333385 ↗ | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis | Terminated | Baxter Healthcare Corporation | Phase 4 | 2001-10-01 | The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective. |
| NCT00333385 ↗ | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis | Terminated | GlaxoSmithKline | Phase 4 | 2001-10-01 | The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective. |
| NCT00333385 ↗ | Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis | Terminated | Roche Pharma AG | Phase 4 | 2001-10-01 | The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CEFTAZIDIME
Condition Name
Clinical Trial Locations for CEFTAZIDIME
Trials by Country
Clinical Trial Progress for CEFTAZIDIME
Clinical Trial Phase
Clinical Trial Sponsors for CEFTAZIDIME
Sponsor Name
